Literature DB >> 33347900

The International Diabetes Federation's guide for diabetes epidemiological studies.

Pablo Aschner1, Suvi Karuranga2, Steven James3, David Simmons4, Abdul Basit5, Jonathan E Shaw6, Sarah H Wild7, Katherine Ogurtsova8, Pouya Saeedi9.   

Abstract

Entities:  

Year:  2020        PMID： 33347900     DOI： 10.1016/j.diabres.2020.108630

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


× No keyword cloud information.
  4 in total

Review 1.  PRDM16 Regulating Adipocyte Transformation and Thermogenesis: A Promising Therapeutic Target for Obesity and Diabetes.

Authors:  Na Jiang; Ming Yang; Yachun Han; Hao Zhao; Lin Sun
Journal:  Front Pharmacol       Date:  2022-04-08       Impact factor: 5.988

2.  Analysis of Diabetes Clinical Data Based on Recurrent Neural Networks.

Authors:  Yuanyuan Lin; Yueli Li; Xuemei Huang; Li Liu; Haitao Wei; Xinyu Zou
Journal:  Comput Intell Neurosci       Date:  2022-06-27

3.  A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study.

Authors:  Soree Ryang; Sang Soo Kim; Ji Cheol Bae; Ji Min Han; Su Kyoung Kwon; Young Il Kim; Il Seong Nam-Goong; Eun Sook Kim; Mi-Kyung Kim; Chang Won Lee; Soyeon Yoo; Gwanpyo Koh; Min Jeong Kwon; Jeong Hyun Park; In Joo Kim
Journal:  Diabetes Obes Metab       Date:  2022-06-09       Impact factor: 6.408

Review 4.  Fibroblast Growth Factor in Diabetic Foot Ulcer: Progress and Therapeutic Prospects.

Authors:  Ye Liu; Yiqiu Liu; Junyu Deng; Wei Li; Xuqiang Nie
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-14       Impact factor: 5.555
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.